Medimmune Limited

Adc Therapeutics Sa

Jay Marshall Feingold

Jens Wuerthner

Anna Berkenblit

David Rodney Ungar

Patricius Hendrikus Cornelis Van Berkel

Daniel Stephen Johnston

Gary Dukart

John Hartley

Francesca Zammarchi

Christina Marie Coughlin

Andrew Louis Strahs

Lisa Skelton

Charles Michael Zacharchuk

James Joseph Gibbons

The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).

Dosage regimes for the administration of an anti-CD19 ADC

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Combination therapy with an anti-CD25 antibody-drug conjugate

The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS). 

Dosage regimes for the administration of an anti-CD25 ADC

The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).

Growing community of inventors

Murray Hill, NJ, United States of America

Jay Marshall Feingold